| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2017: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2016: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, we show that S-equol increased pancreatic beta-cell growth, viability, and insulin secretion through activation of G-protein coupled receptor (Gs class). Administration of S-equol suppressed against streptozotocin-induced hyperglycemia by preserving beta-cell mass in mice. These results suggest that S-equol may be useful for an anti-type 2 diabetic agent.
|
